Germany 's Immatics Biotechnologies has signed a partnership agreement with Danish biotech firm catalyst . They 'll combine their technologies to develop several stem cell - specific bispecific immunotherapies against cancer . Under the financial terms of the deal , Immatics will get a $ 54 m initial investment , up to $ 550 m in " milestone " funding and tiered royalties on pharmaceutical sales . Genmab has the option to expand the partnership if it is economically viable .
Germany's Immatics Biotechnologies has signed a licensing agreement with Danish biotech firm Genmab. They'll combine their technologies to develop several T cell-engaging bispecific immunotherapies against cancer. Under the financial terms of the deal, Immatics will get a $54m initial fee, up to $550m in "milestone" payments and tiered royalties on product sales. Genmab has the option to expand the partnership if it is economically viable.